biostudies-literatureAli WASGuangdong Basic and Applied Basic Research FoundationNational Nature Science Foundation of China10732748221148912https://www.ebi.ac.uk/biostudies/studies/S-EPMC9830708biostudies-literatureUnknown30<h4>Background</h4>We aimed to investigate the determinant factors of anti-PD-1 therapy outcome in nasopharyngeal carcinoma (NPC).<h4>Methods</h4>In this retrospective study, we included 64 patients with recurrent/metastatic NPC. The association of patients' characteristics, C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), and lactate dehydrogenase (LDH) with survival benefit of anti-PD-1 therapy were analyzed using Cox regression models and Kaplan-Meier analyses. Patients were divided based on the median value of CRP, NLR or LDH into different subgroups.<h4>Results</h4>At a median follow-up time of 11.4 months (range: 1-28 months), median progression-free survival (PFS) and overall survival (OS) were 1.9 months (95% CI, .18-3.6) and 15 months (95% CI, 10.9-19.1) months, resCancer control : journal of the Moffitt Cancer CenterPretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.PMC983070882002409, 81872201, 818724992020A1515010020, 2018A0303130243Ma YZhang LZhao YAli WASPan HLiao JYang ZYang YHuang YFang WHuang XWu YHong SZhao HfalsePretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.<h4>Background</h4>We aimed to investigate the determinant factors of anti-PD-1 therapy outcome in nasopharyngeal carcinoma (NPC).<h4>Methods</h4>In this retrospective study, we included 64 patients with recurrent/metastatic NPC. The association of patients' characteristics, C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), and lactate dehydrogenase (LDH) with survival benefit of anti-PD-1 therapy were analyzed using Cox regression models and Kaplan-Meier analyses. Patients were divided based on the median value of CRP, NLR or LDH into different subgroups.<h4>Results</h4>At a median follow-up time of 11.4 months (range: 1-28 months), median progression-free survival (PFS) and overall survival (OS) were 1.9 months (95% CI, .18-3.6) and 15 months (95% CI, 10.9-19.1) months, res2023-01-01T00:00:00Z2023 Jan-Dec2026-05-27T23:13:51.58Z2024-11-20T14:29:23.314ZS-EPMC98307083659216210.1177/10732748221148912